Sawai Pharmaceutical and Nipro announced the addition of pediatric dosage and administration for the generic version of daptomycin. The intended uses are believed to include pediatric cases of sepsis and deep skin infections, as well as injuries, burns and surgical wounds.
Sawai Pharmaceutical and Nipro announced plans to add pediatric dosage and administration for the generic version of the cyclic lipopeptide antibiotic Cubicin Injection 350 mg (generic name: daptomycin). The article does not provide details of the specific additional conditions or the applicable age range.
The drug concerned is a generic product referred to as Cubicin Injection 350 mg, and is expected to be used primarily in pediatric cases of sepsis and deep skin infections, as well as injuries, burns and surgical wounds.
The development was reported by Nikkan Yakugyo as information announced on the 28th. The article does not specify any additional figures or a confirmed timeline.